The DOI matches its Crossref record; 68 of the 70 references it cites were found in a registry or an index.
USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression
Open accessPublished version of a preprint
Abstract
Increasing evidence links deregulation of the ubiquitin-specific proteases 22 (USP22) deubitiquitylase to cancer development and progression in a select group of tumor types, but its specificity and underlying mechanisms of action are not well defined. Here we show that USP22 is a critical promoter of lethal tumor phenotypes that acts by modulating nuclear receptor and oncogenic signaling. In multiple xenograft models of human cancer, modeling of tumor-associated USP22 deregulation demonstrated that USP22 controls androgen receptor accumulation and signaling, and that it enhances expression of critical target genes coregulated by androgen receptor and MYC. USP22 not only reprogrammed androgen receptor function, but was sufficient to induce the transition to therapeutic resistance. Notably, in vivo depletion experiments revealed that USP22 is critical to maintain phenotypes associated with end-stage disease. This was a significant finding given clinical evidence that USP22 is highly deregulated in tumors, which have achieved therapeutic resistance. Taken together, our findings define USP22 as a critical effector of tumor progression, which drives lethal phenotypes, rationalizing this enzyme as an appealing therapeutic target to treat advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“USP22 functions involve the remodeling of chromatin by removing ubiquitin from histones (H2B and H2A) and activation/stabilization transcription factors.14,15”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Analysis of individual components revealed that 10 of the 11 genes are altered in prostate adenocarcinoma (28); thus, patient survival was stratified for individual components.”
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · cited 1×
“USP22 depletion acted in concert with castration to elicit an enhanced biochemical and cellular response, and based on data presented herein, targeting USP22 should also act in concert with the recently approved CYP17A inhibitor abiraterone acetate, which targets intracrince androgen synthesis (65, 66).”
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 1×
“Based on previous findings that increased androgen receptor activity is sufficient to bypass the response to androgen receptor antagonists (30), the ability of the direct androgen receptor antagonist Casodex to inhibit androgen-mediated androgen receptor activity in the context of USP22 deregulation was determined.”
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198 · cited 1×
“In mouse models of prostate adenocarcinoma, MYC-driven tumor formation is reduced by castration or androgen receptor antagonists (52).”
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916 · cited 10×
“Cancer Res; 74(1) January 1, 2014 Cancer Research 274”
InfluentialAndrogen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902 · cited 1×
“Although UBE2C expression was unchanged, CDC20 and CDK1 (34) were both significantly increased to levels seen in other models of CRPC (Fig.”
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Cited by
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
“USP22 was later shown to act as an oncogene product, regulating cell cycle progression, proliferation and apoptosis 126 .”
BackgroundXiong, H., Ni, Z., He, J., Jiang, S., Li, X., He, J., Gong, W., Zheng, L., Chen, S., Li, B., et al. (2017) · Oncogene · doi:10.1038/onc.2016.521 · Cited by 362
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
“However, in addition, the function of USP22 as part of the SAGA complex is critical for the transcriptional activity of oncogenic MYC; hence, deletion of USP22 blocks the transcription of MYC target genes and MYC-induced transformation in vivo 78 .”
BackgroundLi, L., Osdal, T., Ho, Y., Chun, S., McDonald, T., Agarwal, P., Lin, A., Chu, S., Qi, J., Li, L., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.08.001 · Cited by 234
“, 2008) associated with poor prognosis in a variety of cancers (Schrecengost et al., 2014).”
BackgroundPal, A., Young, M. A., & Donato, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1211 · Cited by 199
Metadata
- Authors
- Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., Visakorpi, T., DeMarzo, A. M., McMahon, S. B., & Knudsen, K. E.
- Affiliations
- Johns Hopkins University (US)
- Authors' Affiliations: Departments of 1Cancer Biology, 2Urology, 3Radiation Oncology, 4Pathology, and 5Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; 6Sidney Kimmel Comprehensive Cancer Center; 7Department of Pathology, Johns Hopkins University, Baltimore, Maryland; and 8Institute of Biomedical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
- Corresponding author
- Knudsen, Karen E.
- ORCID
- Venue
- Cancer Research
- Published
- 2014-01-01
- Volume
- 74
- Issue
- 1
- Pages
- 272-286
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3947329
- OpenAlex
- W2162790141
- Cited by
- 126
- References
- 70
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 12 · 2023: 16 · 2022: 12 · 2021: 17 · 2020: 12 · 2019: 11 · 2018: 8 · 2017: 13 · 2016: 5 · 2015: 4 · 2014: 7
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA159945, F31CA165475, F32CA156989, R01CA099996, R01CA164834, P30CA056036)
- National Institute of Environmental Health Sciences (R01ES016675)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- USP22, deubiquitinase, androgen receptor, c-Myc, oncogenic signaling, treatment resistance, tumor progression, xenograft models, therapeutic target
- MeSH terms
- Adenocarcinoma, Animals, Disease Models, Animal, Humans, Male, Receptors, Androgen, Thiolester Hydrolases, Biomarkers, Tumor, Gene Expression, Gene Expression Regulation, Neoplastic, Mice, SCID, Disease Progression, Cell Culture Techniques, Ubiquitin Thiolesterase, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1954
- The paper
- Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., Visakorpi, T., DeMarzo, A. M., McMahon, S. B., & Knudsen, K. E. (2014). USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1954
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.